Table 2.
Meta-regression analysis with proportion of patients with higher eosinophil counts for identification of effect modification of COPD-related covariates on the association between triple therapy and study outcomes in COPD patients.
| ICS/LABA | LAMA/LABA | |||
|---|---|---|---|---|
| Outcome | Slope | p | Slope | p |
| Mortality | −0.16 | 0.545 | −0.74 | 0.006 |
| Annual rate of moderate/severe exacerbation | −0.31 | <0.001 | −0.50 | <0.001 |
| Change of SGRQ | −2.67 | <0.001 | −3.09 | <0.001 |
| Change of FEV1 | NA | NA | ||
| Adverse event | 0.00 | 0.997 | 0.03 | 0.272 |
| Serious adverse event | −0.01 | 0.911 | −0.05 | 0.421 |
| Pneumonia | −0.10 | 0.479 | 0.71 | <0.001 |
| Cardiovascular event | 0.14 | 0.328 | −0.36 | 0.157 |
| Respiratory tract infection | 0.16 | 0.247 | 0.11 | 0.673 |